CHA2DS2‐VASc scores for outcome prediction in acute ischaemic stroke

Background The CHADS2 and CHA2DS2‐VASc scores are clinical risk stratification instruments that are used clinically to assess the risk of stroke in patients with atrial fibrillation (AF). The aim of this study was to evaluate whether the prestroke CHADS2 and CHA2DS2‐VASc scores could be useful for p...

Full description

Saved in:
Bibliographic Details
Published in:European journal of clinical investigation 2018-03, Vol.48 (3), p.n/a
Main Authors: Su, Chun‐Hung, Tsao, Teng‐Fu, Chen, An‐Chih, Chang, Kai‐Wei, Yang, Yi‐Sun, Ueng, Kwo‐Chang, Tsai, Chin‐Feng
Format: Article
Language:English
Subjects:
acute ischaemic stroke
atrial fibrillation
Cardiac arrhythmia
Cerebral infarction
CHA2DS2‐VASc score
Clinical outcomes
Discharge
Fibrillation
Health risks
Infarction
infarction severity
Magnetic resonance imaging
Patients
Predictions
Stenosis
Stroke
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background The CHADS2 and CHA2DS2‐VASc scores are clinical risk stratification instruments that are used clinically to assess the risk of stroke in patients with atrial fibrillation (AF). The aim of this study was to evaluate whether the prestroke CHADS2 and CHA2DS2‐VASc scores could be useful for predicting infarction severity and long‐term outcomes in patients with acute ischaemic stroke. Materials and methods This prospective study included all 1494 patients who had acute ischaemic stroke without haemorrhagic transformation which was evidenced with magnetic resonance (MR) imaging during hospitalization. Total infarction volume and arterial stenosis score were calculated based on MR imaging. National Institutes of Health Stroke Scale scores (NIHSSs) were obtained at admission and discharge by board‐certified neurologists. The clinical outcomes were defined as composite endpoints of restroke and mortality and were recorded with the mean follow‐up period of 37.5 months. Results There were 195 (13.1%) patients with AF. The patients with AF had significantly higher median CHADS2 and CHA2DS2‐VASc scores than the patients without AF (P 
ISSN:0014-2972
1365-2362
DOI:10.1111/eci.12884